ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.-Reference-Cited by-同舟云学术

ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.

Published:2016-05-20 Issue:15_suppl Volume:34 Page:502-502
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Gianni Luca¹,Mansutti Mauro²,Anton Antonio³,Calvo Lourdes⁴,Bisagni Giancarlo⁵,Bermejo Begoña⁶,Semiglazov Vladimir⁷,Thill Marc⁸,Chacon Jose Ignacio⁹,Chan Arlene¹⁰,Morales Serafin¹¹,Alvarez Isabel¹²,Plazaola Arrate¹³,Zambetti Milvia¹⁴,Redfern Andrew D.¹⁵,Dittrich Christian¹⁶,Dent Rebecca Alexandra¹⁷,Magazzu' Domenico¹⁸,Valagussa Pinuccia¹⁹,Tusquets Ignacio²⁰

Affiliation:

1. Department of Medical Oncology, San Raffaele Scientific Institute, Milano, Italy;

2. Department of Oncology, University Hospital of Udine, Udine, Italy;

3. Hospital Universitario Miguel Servet, Zaragoza, Spain;

4. Complejo Hospitalario Universitario de A Coruña, A Coruna, Spain;

5. Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy;

6. Hospital Clinico Universitario Valencia, Valencia, Spain;

7. NN Petrov Research Institute of Oncology, St Petersburg, Russia;

8. Agaplesion Markus Krankenhaus, Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main, Germany;

9. Hospital Virgen de la Salud, Toledo, Spain;

10. Breast Cancer Research Centre - WA & Curtin University, Perth, Australia;

11. Medical Oncology Department, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain;

12. Hospital Donostia, San Sebastian, Spain;

13. Onkologikoa, San Sebastián, Spain;

14. San Raffaele Hospital, Milan, Italy;

15. Royal Perth Hospital, Perth, WA, Australia;

16. Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna), Kaiser Franz Josef-Spital, Vienna, Austria, Vienna, Austria;

17. National Cancer Center Singapore, Singapore, Singapore;

18. Fondazione Michelangelo, Milano, Italy;

19. Fondazione Michelangelo, Milan, Italy;

20. Hospital Del Mar Sericio Oncologia Medica, Barcelona, Spain;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.34.15_suppl.502

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oxygen-rich chemotherapyviamodified Abraxane to inhibit the growth and metastasis of triple-negative breast cancer;Biomaterials Science;2019

2. Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m2) Followed by Fluorouracil, Epirubicin, and Cyclophosphamide Therapy as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer;Clinical Breast Cancer;2018-10

3. Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?;Cancer Treatment Reviews;2017-11

4. New chemotherapies in breast cancer;memo - Magazine of European Medical Oncology;2017-08-22

5. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017;Annals of Oncology;2017-08